IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of “Moderate Buy” by Brokerages

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has received an average recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $48.6875.

A number of research analysts recently commented on IDYA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Guggenheim reaffirmed a “buy” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, February 18th. Truist Financial increased their price target on IDEAYA Biosciences from $59.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $49.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th.

Insider Buying and Selling

In related news, Director Jeffrey Stein bought 50,000 shares of the stock in a transaction on Monday, March 2nd. The stock was bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the purchase, the director directly owned 54,281 shares in the company, valued at $1,789,101.76. This represents a 1,167.95% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.50% of the stock is owned by insiders.

Institutional Investors Weigh In On IDEAYA Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC lifted its holdings in shares of IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after acquiring an additional 580 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its position in shares of IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in IDEAYA Biosciences in the 3rd quarter valued at approximately $38,000. Global Retirement Partners LLC purchased a new stake in IDEAYA Biosciences in the fourth quarter valued at approximately $61,000. Finally, Abich Financial Wealth Management LLC purchased a new stake in IDEAYA Biosciences in the third quarter valued at approximately $58,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $34.27 on Wednesday. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of -26.16 and a beta of 0.09. The company’s 50-day moving average is $33.76 and its two-hundred day moving average is $31.69. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.09. The firm had revenue of $21.75 million during the quarter, compared to analysts’ expectations of $5.95 million. The business’s quarterly revenue was up 55.7% on a year-over-year basis. During the same period last year, the company earned ($1.49) EPS. As a group, equities analysts anticipate that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.